Slide 1: Q3'FY26 Earnings Call Supplemental Presentation
Q3’FY26 Earnings Call Supplemental Presentation May 6, 2026 This presentation contains forward-looking statements. See slide 2 for important cautionary information.
Slide 2: Forward-Looking Statements
This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking Statements Statements made in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking statements tha
Slide 3: Vision and Mission
Vision and Mission To expand the curative power of radiation therapy to improve as many lives as possible. To think, act, and execute beyond expectations every day to deliver better, safer radiation therapy solutions and help patients get back to living their lives, faster. Proprietary and Confident
Slide 4: Q3'FY26 and YTD Q3'FY26 Financials
Q3’FY26 and YTD Q3’FY26 Financials Highlights KEY FINANCIAL METRICS $M Q3 Y/Y YTD Y/Y Excluding current quarter restructuring expenses of $6.5M and the prior year reversal of accrued compensation of $3.2M, operating Revenues $104.8M -7% $301.0M -9% expenses decreased $6.0M, or 18%, versus the prio
Slide 5: China Deferred Margin Impact
China Deferred Margin Impact Total Margin Deferral Impact FY25 FY26 Due to JV accounting rules, 49% $k YTD Q1 Q2 Q3 of total margin is deferred upon Net China Margin Impact (Deferral) / Release (7,666) (1,081) 1,220 (96) shipment to the JV and margin is released when the JV ships the Total Gross M
Slide 6: RPO Disclosure Change
RPO Disclosure Change There is NO change to any of the As provided in our Form 10-K/A and the 10-Q/A filed on February 17, 2026, we revised following items: prior disclosure for remaining performance obligations (“RPO”) included in Note 2, Financial statements – income Revenue. Below is a short su
Slide 7: FY26 Guidance
FY26 Guidance Withdrawing FY26 Guidance due to geopolitical uncertainties Transformation plan tracking ahead of plan: We are well on track to exceed the $12 million we originally targeted for fiscal year 2026. We continue to believe that at least $25 million of these improvements should be rea
Slide 8: Thank you
Thank you Proprietary and Confidential Property of Accuray 8
Slide 9: GAAP to Adjusted EBITDA Q3 FY'26 and Q3 FY'25
GAAP to Adjusted EBITDA Q3 FY’26 and Q3 FY’25 Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization, Stock-Based Compensation, Changes in Fair Value of Warrant Liability, and Certain Non-Recurring, Irregular and One-Time Items (Adjusted EBITDA) T
Slide 10: GAAP to Adjusted EBITDA YTD Q3 FY'26 and YTD Q3 FY'25
GAAP to Adjusted EBITDA YTD Q3 FY’26 and YTD Q3 FY’25 Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization, Stock-Based Compensation, Changes in Fair Value of Warrant Liability, and Certain Non-Recurring, Irregular and One-Time Items (Adjusted E
Slide 11: GAAP to Adjusted EBITDA Q2 FY'26 and Q2 FY'25
GAAP to Adjusted EBITDA Q2 FY’26 and Q2 FY’25 Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization, Stock-Based Compensation, Changes in Fair Value of Warrant Liability, and Certain Non-Recurring, Irregular and One-Time Items (Adjusted EBITDA) T
Slide 12: GAAP to Adjusted EBITDA Q1 FY'26 and Q1 FY'25
GAAP to Adjusted EBITDA Q1 FY’26 and Q1 FY’25 Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization, Stock-Based Compensation, Changes in Fair Value of Warrant Liability, and Certain Non-Recurring, Irregular and One-Time Items (Adjusted EBITDA) T
Slide 13: GAAP to Adjusted EBITDA FY2025
GAAP to Adjusted EBITDA FY2025 Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization, Stock-Based Compensation, Changes in Fair Value of Warrant Liability, and Certain Non-Recurring, Irregular and One-Time Items (Adjusted EBITDA) Twelve Months En
Slide 14: Gross Margin to Gross Margin Excluding China Margin Impact Q3 FY'26
Gross Margin to Gross Margin Excluding China Margin Impact Q3 FY’26 Reconciliation of Gross margin to Gross margin excluding China Margin Impact Three Months Ended March 31, $K 2026 Total Net Revenue $ 104,845 Total Cost of Revenue (79,551) Gross Profit 25,294 China Margin Deferral (96) Gross Profit
Slide 15: Gross Margin to Gross Margin Excluding China Margin Impact Q2 FY'26
Gross Margin to Gross Margin Excluding China Margin Impact Q2 FY’26 Reconciliation of Gross margin to Gross margin excluding China Margin Impact Three Months Ended December 31, $K 2025 Total Net Revenue $ 102,241 Total Cost of Revenue (78,169) Gross Profit 24,072 China Margin Release 1,220 Gross Pro
Slide 16: Gross Margin to Gross Margin Excluding China Margin Impact Q1 FY'26
Gross Margin to Gross Margin Excluding China Margin Impact Q1 FY’26 Reconciliation of Gross margin to Gross margin excluding China Margin Impact Three Months Ended September 30, $K 2025 Total Net Revenue $ 93,942 Total Cost of Revenue (66,931) Gross Profit 27,011 China Margin Deferral (1,081) Gross
Slide 17: Gross Margin to Gross Margin Excluding China Margin Impact FY25
Gross Margin to Gross Margin Excluding China Margin Impact FY25 Reconciliation of Gross margin to Gross margin excluding China Margin Impact Twelve Months Ended June 30, $K 2025 Total Net Revenue $ 458,505 Total Cost of Revenue (311,538) Gross Profit 146,967 China Margin Deferral (7,666) Gross Profi